8-K: Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

Serina Therapeutics appoints Dr. Stephen Brannan, a seasoned neuroscience drug developer, to its Board of Directors and announces the departure of Remy Gross.

Summary

• Serina Therapeutics appointed Dr. Stephen Brannan to its Board of Directors, effective May 22, 2025.
• Dr. Brannan will serve on the Compensation Committee.
• He brings extensive experience in neuroscience and neuropsychiatry drug development, including leading the clinical strategy for KarXT at Karuna Therapeutics, which was later acquired by Bristol Myers Squibb for $14 billion.
• Remy Gross departed from the Board of Directors, effective May 22, 2025; his departure was not due to any disagreement with the company.
• Serina Therapeutics filed a certificate of correction to the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock to clarify the adjustment of the conversion price.
• The correction ensures that the conversion price of $5.18 per share is subject to adjustment pursuant to Section 9(b) of the Certificate of Designations.

Sentiment

Score: 7

Explanation: The appointment of an experienced director is a positive sign, and the clarification of stock terms reduces uncertainty. However, the departure of a director introduces a slight negative element.

Positives

• The appointment of Dr. Stephen Brannan brings significant expertise in neuroscience drug development to Serina's Board.
• Dr. Brannan's experience with KarXT, a successful CNS therapy, could benefit Serina's pipeline development.
• The certificate of correction clarifies the terms of the Series A Convertible Preferred Stock, reducing potential ambiguity for investors.

Negatives

• The departure of Remy Gross from the Board of Directors, although not due to disagreement, may represent a loss of experience and guidance.

Risks

• The company is still in the clinical stage, and the success of its pipeline is not guaranteed.
• The biotechnology industry is subject to regulatory and market risks.

Future Outlook

Serina Therapeutics aims to advance its pipeline of product candidates, leveraging the POZ Platform to improve the efficacy and safety profiles of various therapeutic modalities.

Management Comments

• Steve Ledger, CEO of Serina Therapeutics, stated that Dr. Brannan's clinical and strategic expertise in neuroscience drug development is highly aligned with Serina's focus on long-acting treatments for movement disorders and other CNS conditions.
• Steve Ledger thanked Remy Gross for his contributions to Serina's growth.

Industry Context

The appointment of Dr. Brannan, who played a key role in the development of KarXT, highlights the increasing focus on innovative treatments for neurological diseases and the potential for significant value creation in this sector, as demonstrated by Karuna's acquisition.

Comparison to Industry Standards

• Karuna Therapeutics' $14 billion acquisition by Bristol Myers Squibb in 2024 sets a high benchmark for CNS drug development success.
• Dr. Brannan's experience at Takeda, Novartis, Cyberonics (now LivaNova), and Eli Lilly provides a broad perspective on industry best practices in clinical development.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may view the appointment of Dr. Brannan positively, given his track record.
• The clarification of the Series A Convertible Preferred Stock terms provides greater transparency for investors.

Next Steps

• Serina Therapeutics will continue to advance its pipeline of drug candidates.
• Dr. Brannan will contribute to the strategic development of long-acting CNS therapeutics.

Key Dates

Keywords

Board of Directors, Stephen Brannan, Remy Gross, Certificate of Correction, Series A Convertible Preferred Stock, Neuroscience, Karuna Therapeutics, Serina Therapeutics, Appointment, Departure